Another death related to allogenic CAR-T cell therapy – European Biotechnology
European Biotechnology |
Another death related to allogenic CAR–T cell therapy
European Biotechnology Following the death of a patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA put a hold on two clinical Phase I trails with UCART123, French Cellectis SA's allogenic CAR–T therapies. Preliminary results from two trials in CD19+ … |
